Brokerages Set Edwards Lifesciences Corporation (NYSE:EW) PT at $96.45

Edwards Lifesciences Corporation (NYSE:EW) has earned an average recommendation of “Moderate Buy” from the twenty-eight research firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, nine have given a hold recommendation, fifteen have issued a buy recommendation and three have given a strong buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $96.8182.

A number of brokerages have issued reports on EW. Oppenheimer lowered Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 8th. UBS Group restated a “neutral” rating and set a $95.00 price objective (up from $92.00) on shares of Edwards Lifesciences in a research report on Monday, January 12th. TD Cowen upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Friday, January 9th. Evercore ISI reissued an “outperform” rating and issued a $94.00 price target on shares of Edwards Lifesciences in a research note on Monday, January 5th. Finally, Truist Financial set a $92.00 price target on shares of Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, December 5th.

Edwards Lifesciences Stock Down 0.9%

Shares of NYSE EW opened at $83.70 on Monday. The stock has a market cap of $48.57 billion, a PE ratio of 36.08, a P/E/G ratio of 3.22 and a beta of 0.95. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 12-month low of $65.94 and a 12-month high of $87.89. The company has a 50-day moving average of $84.99 and a 200 day moving average of $80.80.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The business had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same period in the previous year, the firm posted $0.67 EPS. The business’s revenue for the quarter was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, sell-side analysts predict that Edwards Lifesciences will post 2.45 EPS for the current fiscal year.

Insider Activity

In other news, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction on Monday, November 10th. The stock was sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the completion of the transaction, the chief financial officer directly owned 39,898 shares in the company, valued at approximately $3,314,725.84. This represents a 24.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 1,020 shares of the firm’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $82.55, for a total value of $84,201.00. Following the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,816,265.10. The trade was a 4.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 57,824 shares of company stock valued at $4,863,323 in the last quarter. Insiders own 1.29% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

Several large investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in Edwards Lifesciences by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company’s stock valued at $5,472,147,000 after purchasing an additional 365,581 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Edwards Lifesciences by 4.9% during the third quarter. Wellington Management Group LLP now owns 20,804,416 shares of the medical research company’s stock worth $1,617,959,000 after buying an additional 977,933 shares during the period. Bank of New York Mellon Corp grew its stake in shares of Edwards Lifesciences by 8.1% in the third quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock valued at $1,478,425,000 after buying an additional 1,423,365 shares in the last quarter. Jennison Associates LLC raised its holdings in shares of Edwards Lifesciences by 19.6% in the 3rd quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock valued at $1,085,574,000 after buying an additional 2,287,783 shares during the period. Finally, Geode Capital Management LLC lifted its stake in Edwards Lifesciences by 0.4% during the 2nd quarter. Geode Capital Management LLC now owns 12,722,416 shares of the medical research company’s stock worth $990,074,000 after acquiring an additional 45,555 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.